"We are increasingly also exploring additional patient populations for which a brain penetrant PI3K/mTOR inhibitor may provide significant advantages over the standard of care".
Given that the company is already planning for commercialisation, and has been doing marketing research, they are also signalling their intention to expand the potential market.
Companies selling moonbeams and unicorn poo also hype their products, but we clearly are not in that category.
- Forums
- ASX - By Stock
- Ann: Kazia releases final data from P2 paxalisib trial
"We are increasingly also exploring additional patient...
-
- There are more pages in this discussion • 51 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)